Trial Profile

A registrational trial of ozuriftamab vedotin in squamous cell carcinoma of the head and neck

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozuriftamab vedotin (Primary)
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use

Most Recent Events

06 May 2025 According to BioAtla media release, company is utilizing Fast Track Designation for additional discussions with the USFDA to obtain guidance on this proposed Phase 3 study, in treatment-refractory, metastatic HPV-positive SCCHN.
20 May 2024 New trial record
14 May 2024 According to BioAtla media release, company anticipate FDA meeting in 2H 2024 for potential registrational trial in SCCHN.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com